Postdischarge oral versus injectable anticoagulation following major orthopedic surgery

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1222-1228

  Shorr, Andrew F ^a,b   Nutescu, Edith A ^c   Farrelly, Eileen ^d   Horblyuk, Ruslan ^e   Happe, Laura E ^d,f   Franklin, Meg ^f  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d XCENDA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f NONE

Author keywords

Anticoagulation; Major orthopedic surgery; Prophylaxis; Venous thromboembolism

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; COST CONTROL; DATA BASE; DRUG COST; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; ORTHOPEDIC SURGERY; OUTPATIENT CARE; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; RETROSPECTIVE MORAL JUDGMENT;

EID: 50249116034     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L113     Document Type: Article

References (24)

1. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):338S-400S.
2. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37.
3. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(suppl 1):I4-8.
4. Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med 2002;162:1465-71.
5. White RH, Romano PS, Zhou H, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31.
6. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Thromboembolism in the outpatient setting. Arch Intern Med 2007;167:1471-5.
7. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9-15.
8. Cohen AT, Bailey CS, Alikhan R, et al. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Throm Haemost 2001;85:940-1.
9. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002;162:1966-71.
10. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 2001;135:858-69.
11. American Academy of Orthopaedic Surgeons (AAOS). Clinical guidelines and performance measures. www.aaos.org/Research/guidelines/guide.asp (accessed 2007 Oct 25).
12. Anderson FA Jr, White K; Hip and Knee Registry Investigators. Prolonged prophylaxis in orthopedic surgery: insights from the United States. Semin Throm Hemost 2002;28(suppl):43-6.
13. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-26.
14. Colwell CW, Collis DK, Paulson R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 1999;81:932-40.
15. Samama CM, Vray M, Barre J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002;162:2191-6.
16. Fitzgerald RH, Spiro TE, Trowbridge AA, et al. Prevention of venous thromboembolic disease following primary total knee arthroplasty. J Bone Joint Surg Am 2001;83-A:900-6.
17. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
19. Shorr AF, Kwong LM, Sarnes M, et al. Venous thromboembolism after orthopaedic surgery: implications of the choice for prophylaxis. Thrombosis Res 2007;121:17-24.
20. Vera-Llonch M, Hagiwara M, Oster G. Clinical and economic consequences of bleeding following major orthopedic surgery. Thromb Res 2006;117:569-77.
21. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-6.
22. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 1995;155:757-64.
23. Friedman RJ, Dunsworth GA. Cost analyses of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop Relat Res 2000;370:171-82.
24. Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 2004;22:605-20.